Bristol Myers Squibb announces departure of Chief Commercial Officer
pharmafile | July 24, 2018 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Bristol-Myers Squibb, bristol myers squibb, commerical executive, marketing, sales
Bristol Myers Squibb has announced that Executive Vice President and Chief Commercial Officer, Murdo Gordon, who has been with the company for nearly 30 years, is to leave the company on 3 August 2018 in order to pursue another opportunity.
Gordon, who joined the company in 1989, graduated with a BSc in Cell and Molecular Biology from Concordia University in Montreal in the same year. For the first 14 years of his career Gordon worked in a variety of sales and marketing roles in his native Canada before moving to the US in 2003, at which point he took on senior commercial leadership positions in a number of different areas. Gordon who has acted as the Director of Robert Wood Johson University Hospital in New Brunswick, New Jersey, came into his current role in 2016.
Giovanni Caforio, Chairman and Chief Executive Officer at Bristol-Myers Squibb thanked Gordon in commenting: “On behalf of the company, I want to thank Murdo for his leadership and the important contributions he’s made in his many years with Bristol-Myers Squibb. Murdo helped build a highly performing commercial organization and developed a strong bench of talent, contributing to our competitive position in the market and our success in delivering innovative medicines to patients.”
Bristol Myers Squibb has said that the appointment of a new Chief Commercial Officer will be announced at a later date.
Related Content
Bristol Myers Squibb reports positive results for psoriatic arthritis treatment
Bristol Myers Squibb (BMS) has presented new data from its phase 3 POETYK PsA-1 trial, …
BioNTech and Bristol Myers Squibb collaborate on bispecific antibody for solid tumours
BioNTech and Bristol Myers Squibb (BMS) have entered a partnership to collaboratively develop and commercialise …
Bristol Myers Squibb receives positive CHMP opinion for Opdivo treatment
Bristol Myers Squibb (BMS) has received a positive opinion from the Committee for Medicinal Products …
